Black Diamond Therapeutics Inc [BDTX] stock is trading at $5.57, up 11.85%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BDTX shares have gain 9.00% over the last week, with a monthly amount glided 47.35%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Stifel upgraded its rating to Buy on June 30, 2023, and elevated its price target to $10. On June 28, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $11 on the stock. Wedbush upgraded its rating to a Outperform but stick to its price target of $10 on June 27, 2023. Wedbush downgraded its rating to a Neutral. H.C. Wainwright downgraded its rating to Neutral for this stock on March 22, 2022. In a note dated September 30, 2021, Stifel initiated an Hold rating and provided a target price of $10 on this stock.
Black Diamond Therapeutics Inc [BDTX] stock has fluctuated between $1.43 and $6.85 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $5.57 at the most recent close of the market. An investor can expect a potential return of 151.35% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is 14.46 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.18 points at the first support level, and at 4.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.78, and for the 2nd resistance point, it is at 5.98.
Ratios To Look Out For
For context, Black Diamond Therapeutics Inc’s Current Ratio is 6.82. Also, the Quick Ratio is 6.82, while the Cash Ratio stands at 2.86.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Oct 17 ’23 when 0.4 million shares were purchased. Director, Behbahani Ali completed a deal on Jul 05 ’23 to buy 1.0 million shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 0.94 million shares on Jul 05 ’23.
